ArticleJournal of cancer research and clinical oncology2009
Elimination of high-risk human papillomavirus type HPV16 infection by 'Praneem' polyherbal tablet in women with early cervical intraepithelial lesions.
Article in Journal of cancer research and clinical oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of commercially available biological agents for the topical treatment of cervical intraepithelial neoplasia: a systematic review.Systematic reviews · 2019Pooled it
- Clinical Outcomes of a Multi-IngredientCancers · 2026Article
- Ellagic acid inhibited cervical cancer growth via blocking the AKT/mTOR/STAT3 pathway.Archives of medical science : AMS · 2026Article
- Review
- Challenges and opportunities to making Indian women cervical cancer free.The Indian journal of medical research · 2023Article
- Effect of a Multi-IngredientCancers · 2023Article
- Natural Bioactives: Back to the Future in the Fight against Human Papillomavirus? A Narrative Review.Journal of clinical medicine · 2022Review
- Plant-Derived Natural Compounds in Genetic Vaccination and Therapy for HPV-Associated Cancers.Cancers · 2020Review
- Topical therapies for the treatment of cervical intraepithelial neoplasia (CIN) 2-3: A narrative review.Gynecologic oncology reports · 2020Review
- Molecular mechanisms in progression of HPV-associated cervical carcinogenesis.Journal of biomedical science · 2019Review
- An Overview on the Anticancer Activity ofInternational journal of molecular sciences · 2018Review
- High-Risk Human Papillomaviral Oncogenes E6 and E7 Target Key Cellular Pathways to Achieve Oncogenesis.International journal of molecular sciences · 2018Review
- Integration of botanicals in contemporary medicine: road blocks, checkpoints and go-ahead signals.Integrative medicine research · 2018Review
- Vaginal drug delivery for the localised treatment of cervical cancer.Drug delivery and translational research · 2017Review
- Beneficial effects of a Coriolus versicolor-based vaginal gel on cervical epithelization, vaginal microbiota and vaginal health: a pilot study in asymptomatic women.BMC women's health · 2017Article
- Human Papillomavirus: Current and Future RNAi Therapeutic Strategies for Cervical Cancer.Journal of clinical medicine · 2015Review
- Anticancer property of Bryophyllum pinnata (Lam.) Oken. leaf on human cervical cancer cells.BMC complementary and alternative medicine · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose'Praneem', a polyherbal formulation developed by us, has successfully completed Phase II efficacy study for treatment of abnormal vaginal discharge due to reproductive tract infections that act as co-factors for HPV persistence. In the present study we evaluated potential anti-HPV activity of Praneem in women infected with high risk HPV type 16.
methodsTwenty women molecularly diagnosed positive for HPV16 infection without or with low grade squamous intraepithelial lesion (LSIL) or inflammation were assigned to receive intra-vaginal, topical application of either Praneem tablet or placebo for 30 days excluding the days of menstrual period and were evaluated for persistence of HPV infection using HPV L1 consensus and HPV type 16-specific PCR as primary outcome.
resultsOne course of Praneem treatment resulted in elimination of HPV in 6 out of 10 (60%) cases. A repeat treatment of four patients with persisting HPV infection resulted in clearance of HPV in two additional cases resulting in an overall 80% clearance of HPV 16 as against a spontaneous clearance of 10% (1/10) seen in the placebo arm. The elimination of HPV DNA was found to be accompanied by marked improvement in clinical symptoms and cytological abnormalities of Praneem-treated patients.
conclusionOur results showed for the first time that a 30-day intra-vaginal application of the Praneem can result in elimination of HPV infection from the uterine cervix.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.